# IL17RA and IL21R Polymorphisms Influence Type 1 Diabetes Predisposition and Autoimmune Phenotypes

Cintia Semzezem, Karla Fabiana Brasil Gomes, Aritania Sousa Santos, Pauline Brochet, Lindiane Gomes Crisostomo, Marcia Regina Soares Correia, Amanda Garage Frade-Barros, Luciano Abreu Brito, Maria Rita Passos-Bueno, Christophe Chevillard, et al.

► To cite this version:

Cintia Semzezem, Karla Fabiana Brasil Gomes, Aritania Sousa Santos, Pauline Brochet, Lindiane Gomes Crisostomo, et al. IL17RA and IL21R Polymorphisms Influence Type 1 Diabetes Predisposition and Autoimmune Phenotypes. Frontiers in Endocrinology, 2025, 16, 10.3389/fendo.2025.1620509. hal-05318088

HAL Id: hal-05318088

https://hal.science/hal-05318088v1

Submitted on 16 Oct 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
1 **IL17RA and IL21R Polymorphisms Influence Type 1 Diabetes Predisposition and Autoimmune**

2 **Phenotypes**

3
4 Cintia Semzezem¹, Karla Fabiana Brasil Gomes¹, Aritania Sousa Santos¹, Pauline Brochet²,
5 Lindiane Gomes Crisostomo¹ Marcia Regina Soares Correia¹, Amanda Garage Frade Barros³,
6 Luciano Abreu Brito⁴, Maria Rita Passos-Bueno⁴, Christophe Chevillard ², Edecio Cunha-Neto³,
7 Maria Elizabeth Rossi da Silva¹*.

8
9 1-Laboratório de Carboidratos e Radioimunoensaios (LIM-18) do Hospital das Clínicas da Faculdade de
10 Medicina da Universidade de São Paulo. Av. Dr. Arnaldo 455, sala 3324, 01246-903. São Paulo, São
11 Paulo, Brazil

12
13 2- French National Institute for Health and Medical Research (INSERM), UMR U1090, Aix Marseille
14 University AMU, TAGC Theories and Approaches of Genomic Complexity, MarMaRa institute, 13288
15 Marseille, France

16
17 3- Heart Institute, Laboratory of Clinical Immunology and Allergy-LIM60- Instituto do Coração-INCOR;
18 Institute for Investigation in Immunology-iii/INCT. Av. Dr. Enéas Carvalho de Aguiar, 44 - Cerqueira
19 César, São Paulo - SP, 05403-900

20 4-Departamento de Genética e Biologia Evolutiva, Instituto de Biociências da Universidade de São Paulo.
21 Rua do Matão, 277, 05422-970, São Paulo, São Paulo, Brazil

22
23 *Corresponding author

24 Maria Elizabeth Rossi da Silva

25 mbeth@usp.br

26
27 Number of Words: 315

28 Number of Tables: 4

29 Number of Figures: 1

30
31
35 **Background:** Although interleukin receptors have been implicated in various autoimmune diseases, their 36 role in type 1 diabetes (T1D) remains underexplored and occasionally inconsistent. To evaluate the 37 impact of polymorphisms in genes encoding the interleukin receptors IL-21R and IL-17RA on T1D 38 susceptibility and other autoimmune manifestations, we analyzed 639 patients with T1D and 653 healthy 39 controls. Selected variants in IL17RA (n=4), IL21R (n=4), were genotyped using the VeraCode 40 GoldenGate assay (Illumina, USA). Autoantibodies were assessed by radioimmunoassay, ELISA, and a 41 radiolabeled iodine receptor assay. Two IL17RA variants were significantly associated with T1D: the 42 rs2241049G allele was linked to increased susceptibility (OR=1.42; p=0.005), whereas the rs879577A 43 allele was related to protection (OR=0.61; p=0.021) and a reduced frequency of anti-tyrosine 44 phosphatase (anti-IA2) autoantibody (OR= 0.52; p=0.010). Additionally, the rs5748863G allele was also 45 associated with a lower frequency of anti-IA2 positivity (OR=0.52; p=0.010). Among IL21R variants, only 46 rs7199138C was associated with an increased risk of T1D (OR=1.33; p=0.018). Moreover, rs2214537G 47 and rs2285452A were linked to a reduced frequency of anti-parietal cell (OR=0.24; p<0.001) and anti- 48 endomysium (OR=0.17; p=0.025) autoantibodies, respectively. In contrast, rs2285452A and rs3093315T 49 were related to a higher frequency of anti-thyroperoxidase (OR=2.38; p=0.028) and TSH receptor (TRAb) 50 autoantibodies (OR=5.90; p=0.024), respectively. These findings suggest that polymorphisms in IL17RA 51 and IL21R genes may contribute to T1D pathogenesis and modulate the presence of pancreatic and 52 extra-pancreatic autoantibodies. 53

53
54 **Keywords:** IL-17RA; IL-21R;Type 1 diabetes, islet autoantibodies, extra-pancreatic
55 autoantibodies

56
57
58
59
60
61

62

INTRODUCTION

63

64

65

66

67

68

Type 1 diabetes (T1D) is a chronic autoimmune disease with a multifactorial etiology involving environmental triggers, genetic susceptibility, and immunological dysregulation that culminate in the destruction of pancreatic β-cells [1,2]. It is characterized by the presence of high-risk HLA-DR3 and DR4 alleles and islet-specific autoantibodies, which typically appear before clinical onset and reflect the underlying autoimmune process [3]. Moreover, T1D is frequently associated with other autoimmune diseases, often accompanied by organ-specific autoantibodies and shared genetic determinants [1,2].

69

70

71

72

73

74

75

76

77

78

79

80

81

82

Recent studies have highlighted the involvement of the Th17 pathway in the immunopathogenesis of T1D, acting independently of the classical Th1 and Th2 pathways. Th17 cells secrete proinflammatory cytokines such as Interleukins IL-17A, IL-21, IL-22, tumor necrosis factor (TNF)-α, and IL-6 [4,5,6], playing pivotal roles in host defense and in the pathogenesis of autoimmune diseases including autoimmune thyroid disease (7) systemic lupus erythematosus and multiple sclerosis [5,6,8-10]. Increased circulating levels of IL-17A (11) and mRNA expression of IL-17A have been observed in circulating memory CD4⁺ T cells from children with new-onset T1D (12); furthermore, local IL-17 production has been detected in pancreatic islets around the time of disease onset (13) and human β-cells were shown to be susceptible to IL-17A-induced apoptosis (12). On the other hand, serum levels of IL-17 or IL-23 — a cytokine known to maintain Th17 cells (14-15), as well as genetic variants in other cytokine genes within the Th17 pathway, such as IL-17 (14), IL-21 (16), and IL-27 (17), were found *by our group* not to influence T1D susceptibility, clinical phenotype or presence of autoantibodies. In addition, two IL-23A gene variants (rs11171806 and rs2066808; GG haplotype) were associated with protection against T1D in the Brazilian population (15).

83

84

85

86

87

88

89

90

In animal models of autoimmune diabetes, IL-17A and Th17 cells have been implicated in disease progression. Interventions with anti-IL-17 antibodies or IL-2 - a negative regulator of Th17 responses—prevented insulitis [18] and remitted diabetes [19], whereas IL-23 administration, which enhances IL-17 and TNF-α production, exacerbated β-cell damage [20]. Additionally, the synergistic effect of IL-17A with IL-21 and IFN-γ has been reported to promote diabetes development [21]. Furthermore, IL-21 overexpression in pancreatic β-cells led to increased expression of inflammatory mediators such as IL-17A, IL-17F, IFN-γ, MCP-1, MCP-2, and IP-10, whereas IL-21R deficiency conferred protection against insulitis and diabetes in NOD mice (22).

91

92

93

However, some studies have challenged the pathogenic role of Th17 cells in experimental autoimmune diabetes models under specific circumstances (23-26). This data is in line with our previous findings in Brazilian patients with T1D (14-17) that suggested that genetic polymorphisms in cytokines of
the Th17 inflammatory pathway may exert a neutral or even protective effect on T1D susceptibility. Few studies evaluated the role of IL17RA and IL21R in human T1D pathogenesis. In prior researches involving Brazilian patients with recent-onset T1D —up to six months after diagnosis, our group reported reduced surface expression of IL-17RA in CD3+CD4+ T cells (14). In this paper, we show that, likewise, IL-21R surface expression is also reduced in CD3+CD4+ T cells from recent-onset T1D patients.

Based on these observations, we hypothesized that genetic variants in the IL17RA and IL21R genes might modulate IL-17 and IL-21 signaling, thereby contributing to T1D pathogenesis. To investigate this, we selected tag single nucleotide polymorphisms (SNPs) in the IL17R and IL21R genes and assessed their associations with T1D susceptibility and with the presence of islet and extra-pancreatic autoantibodies.

104

## 105 MATERIALS AND METHODS

All procedures were conducted in accordance with the Declaration of Helsinki. Approval of the Ethical Committee of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (CAPPesq CAAE 02038312.1.0000.0068) and written consent from patients or parents were obtained before research procedures.

All serum and plasma samples were collected in fasting conditions, according to the kit manufacturers' guidelines. The samples were separated by centrifugation and stored at -80°C and the dosages were promptly performed.

This cross-sectional genotyping study included 639 patients with T1D, attended at the Clinical Hospital and 653 health controls (according to ADA criteria) (27). The inclusion criteria for T1D patients were persistent insulin requirement and the presence of one or more islet autoantibodies. The exclusion criteria considered other types of diabetes (T2D, mature onset diabetes of the young and secondary diabetes) and use of medications except insulin. The control group was composed of healthy people from the army, scouts or college students who agreed to participate in the study. Included islet autoantibody negative individuals with normal fasting glucose and Hb1Ac levels, and no personal or family history of autoimmune diseases (Figure 1).

The demographic and clinical characteristics of the participants are presented in Supplementary Table 1. Compared to controls, T1D patients were younger (25.3 ± 112.8 vs. 28.7 ± 11.6 years), had higher blood glucose levels(192.1±115.8 x 83.6 ±9.8mg/dL) , a higher proportion of females (58.5 x 37.6%), a greater frequency of pancreatic and extra-pancreatic autoantibodies, and a higher proportion of self-reported white skin color (80.3 x 63.6%) (p < 0.001). The mean age at diagnosis was 11.9 ± 7.8
years, and the mean disease duration was 13.2 ± 10.9 years. Approximately 116 patients with T1D were treated with thyroid hormone. One patient had celiac disease, and one had atrophic gastritis.

The expression of IL-21 receptor in CD3+, CD4+ and CD8+ T cells was evaluated by flow cytometry assay in 35 patients (16 females/19 males) aged 8.4 ± 4.4 years with recent-onset T1DM (<6 months of diagnosis) and 25 health controls (12 females/13 males) aged 8.3± 4.1 years. The inclusion and exclusion criteria were the same as those for the genotyping study.

## Selection of Single Nucleotide Polymorphisms (SNPs).

Single nucleotide polymorphisms (SNPs) in the *IL17RA* and *IL21R* genes were selected from the HapMap database (http://hapmap.ncbi.nlm.nih.gov/) based on two populations, considering the high degree of miscegenation in the Brazilian population (32): CEPH (Utah residents with Northern and Western European ancestry; CEU) and Yoruba in Ibadan, Nigeria (YRI). HapMap data were analyzed using Haploview software (www.broad.mit.edu/personal/cbaret/haploview/), a bioinformatics tool used to identify linkage disequilibrium (LD) and determine the “tag” SNPs representing the genetic variability of each LD block in the studied genes (29-30). Selected tag SNPs had a minor allele frequency greater than 10% and were common to both the CEU and YRI populations.

## Molecular Study and Biochemical Evaluation:

Genomic DNA was extracted from fresh peripheral blood cells using a conventional salting-out method (31). Variants in the *IL17RA* and *IL21R* genes were genotyped using the GoldenGate Platform with Veracode technology (Illumina, USA), according to the manufacturer's instructions. Autoantibodies were measured as follows: anti-glutamic acid decarboxylase (anti-GAD65), anti-tyrosine phosphatase (anti-IA2), anti-thyroid peroxidase (anti-TPO), and anti-thyroglobulin (anti-TG) by radioimmunoassay; anti-zinc transporter 8 (anti-ZnT8) by ELISA; anti-parietal cell antibody by direct immunofluorescence; and anti-TSH receptor antibodies (TRAb) by radioreceptor assay.

### Expression of IL-21 receptor analysis by flow cytometry assay:

Peripheral mononuclear blood cells (PMBCs) were separated from blood by centrifugation over Ficoll-Hypaque gradient. PMBCs were washed twice with the staining buffer, phosphate-buffered saline (PBS) containing 2% fetal bovine serum. Cells ($5 \times 10^5$) were stained on ice for 20 min with 10 µL of the following monoclonal antibodies: phycoerythrin-conjugated mouse anti-human IL-21R mAB (R&D systems, Minneapolis, MN), fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD3 (Beckman Coulter, Fullerton, CA), ECD-conjugated mouse anti-human CD4 (Beckman Coulter, Fullerton, CA), and PC5-conjugated mouse anti-human CD8 (Beckman Coulter, Fullerton, CA). Stained cells were
washed twice with 2 mL of PBS-azide for 2 min at 500 g. The cellular button was resuspended in 400 µL of 4% PBS-paraformaldehyde and then analyzed using a Coulter Epics XL-MCL flow cytometer and Summit v 4.0 software (DakoCytomation, USA). We acquired 10.000 events for the analysis of the receptor. The expression of the receptor was analyzed considering the percentage of CD3+, CD4+ and CD8+ T cells expressing the receptor.

## 163 Statistical Analysis

The polymorphic allele was defined as the least frequent allele in the study population and referred to as the rare allele. The distribution of variables was assessed using the Kolmogorov-Smirnov test. Parametric and non-parametric numerical variables were analyzed using Student's t-test and Mann-Whitney U test, respectively. Qualitative variables were compared using the chi-square test or Fisher's exact test, with SPSS® version 18.0. Associations were evaluated under three genetic models: genotypic, dominant, and recessive. Analyses were adjusted for covariates including sex, age, and self-reported skin color when assessing T1D risk. Associations with autoantibody positivity were adjusted for sex, duration of diabetes, and self-reported skin color. A *p*-value < 0.05 was considered statistically significant.

This study was exploratory in nature. So, a convenience sample was used, in which we included all patients diagnosed with T1D seen at the outpatient clinic. The control group was composed of healthy people from the army, scouts or college students who agreed to participate in the study. At any event, taking into account 639 T1D patients and 653 controls the study was adequately powered to detect polymorphisms with minimal allele frequency of 0.1, relative risk of 1.65, alpha 0.05, and power >0.8.

177

## 178 RESULTS

SNPs in *IL17RA* and *IL21R* were in Hardy-Weinberg Equilibrium (HWE) in both groups (Supplementary Table 2). Rare allele frequencies were similar to those observed in the CEU population (Supplementary Table 3).

Two *IL17RA* variants were associated with T1D and remained statistically significant after adjustment for covariates. The rare G allele of rs2241049 conferred a 1.42-fold increased risk for T1D (*p* adj = 0.005), while the AA genotype of rs879577 was implicated in protection against T1D (OR adj = 0.61, *p* adj = 0.021*) (Table 1). Furthermore, the A allele of rs879577 and the GG genotype of rs5748863 were associated with a lower frequency of anti-IA2 autoantibodies (Table 2). No *IL17RA* variants were involved with extra-pancreatic autoantibodies positivity (Supplementary Table 4).
Among *IL21R* variants, only rs7199138 (C allele) conferred increased susceptibility to T1D (OR adj = 1.33, *p* adj = 0.018*) (Table 1). No *IL21R* variants influenced islet autoantibody positivity (Supplementary Table 5), but associations with extra-pancreatic autoantibodies were observed (Table 4). The rs2214537 G allele was related to a lower frequency of anti-parietal cell antibodies (CG+GG: 4.9% vs. CC: 16.9%, *p* < 0.001), and the rs2285452 A allele to a lower frequency of anti-endomysium antibodies (AG+AA: 1.3% vs. GG: 7.3%; *p* adj = 0.025). Conversely, the rs2285452 AA genotype was associated with a higher frequency of anti-thyroid peroxidase antibodies (AA: 48.4% vs. GG+AG: 27.2%, ORadj = 2.38; *p* adj = 0.028), and the rs3093315 T allele with TRAb positivity (ORadj = 5.90, *p* adj = 0.024). In agreement with these data, the frequency of patients with T1D treated with thyroid hormone (levothyroxine) was higher in those carrying rs22285452A (22.16% x 16.63%; OR=1.427; *p*=0.0272). A similar trend was observed for those carrying rs3093315T (21.49% x 17.08%; OR=1.329; *p*= 0.058) (Supplementary Table 6).

A trend toward a higher frequency of anti-thyroglobulin antibodies was associated with rs5992628G (*padj*=0.073).

The expression of IL-21R (median) was reduced in patients with T1D both in CD3+ (27.4 x 35.0%; *p*=0.018) and in CD4+ T cells (10.02 x 17.0%; *p*=0.0028) but similar in CD8+T cells (16.5 x 15.7%; *p*=0.899) in comparison with controls (Supplementary Table 6-7).

## DISCUSSION

Our findings indicate reduced expression of IL21R on peripheral CD4+ T cells in recent-onset T1D patients, which is in line with the reduced surface expression of IL-17RA previously observed by our group (14). In addition, findings suggest that genetic variants in the *IL17RA* and *IL21R* genes are associated with the development of Type 1 Diabetes (T1D) and the production of pancreatic and extra-pancreatic autoantibodies. The observation that the frequencies of the rare alleles closely resemble those of the CEU population aligns with previous studies in the Brazilian population, which reported European ancestry in 77% of T1D patients and 71% of controls (28) (Supplementary Table 3).

Two variants of the *IL17RA* gene were associated with T1D. Individuals carrying the G allele of the intronic rs2241049 variant exhibited a 1.42-fold increased risk of developing T1D. Polymorphisms in non protein-coding, regulatory regions of a given gene may disrupt transcription factor binding sites, altering its transcription and potentially affecting immune system homeostasis. Notably, previous studies reported the loss of binding sites for transcription factor FOXP3, a key regulator of regulatory T cell development (32), for C/EBPβ (33-34), involved in inflammatory gene regulation including IL-17, and NF-Y, which influences gene expression through DNA structure modulation (35). However, the functional implications of the IL17RA rs2241049 variant remain unclear. While this polymorphism conferred protection to psoriasis, a Th17-driven disease successfully treated with anti-IL-17 monoclonal antibodies
(36), it has been associated with increased severity in ulcerative colitis (37), primary lung graft dysfunction and neutrophilia, indicating a potential role in inflammatory responses (38).

Conversely, other IL17RA variants appeared protective. The AA genotype of the missense variant rs879577 is in exon 13 of the IL17RA gene and changes the amino acid sequence at position 367 from alanine to valine. It was associated with a reduced risk of T1D (ORadj = 0.61, padj = 0.021) and it is likely benign according to SIFT and Polyphen. However, we cannot rule out functional effects considering that the two amino acids have structural and biochemical differences. Furthermore, a variant in a coding region may also influence the expression levels of its gene; predictive analyses indicated that the rs879577AA variant may alter the binding site for the transcription factor YY1, which can act as both a repressor and activator of gene transcription (39). This variant also seems to protect against Alopecia Areata (40) and asthma (41). Both rs879577AA and the intronic rs5748863GG variants were linked to a lower frequency of anti-IA2 autoantibodies. Reduced levels of anti-IA2 have been associated with decreased IL-17 production (42). The IL17RA rs5748863G is an intronic variant with no known effect which does not appear to affect transcription factor binding sites. Nonetheless, the trend toward a higher frequency of anti-thyroglobulin antibodies associated with rs5992628G (p=0.073), a 3'UTR variant with no known effect, and previous reports linking the rs4819554G to decreased anti-GAD titers and reduced T1D risk (14) further support the role of IL17RA in autoimmunity. However, 3'UTR variants may hypothetically modify seed sequence binding of microRNAs, which are negative regulators of gene/protein expression. Our data imply that IL17RA polymorphisms affecting transcriptional regulation may influence T1D risk, potentially through epigenetic mechanisms governing gene expression plasticity. The expression of IL-17 signaling apparatus and of IL-17 receptors in islets might influence T1D progression (43).

The rs7199138 C allele of the *IL21R* gene was also associated with increased T1D susceptibility (OR = 1.33, padj = 0.018). This variant may create a binding site for FOXP3, a negative regulator of the immune system, while disrupting the c-Ets1 binding site, which is crucial for cytokine and chemokine gene expression and lymphoid cell function. Ets1 deficiency in T cells has been linked to SLE-like autoimmunity in mice (44). Additionally, *IL21R* polymorphisms were associated with lower frequencies of autoantibodies against non-pancreatic antigens, such as parietal cells (rs2214537G: 4.9% vs. 16.9%, p < 0.001) and endomysium (rs2285452A: 1.3% vs. 7.3%, padj = 0.025). Variants also influenced autoimmune thyroid disease markers, with higher frequencies of TRAb (rs3093315T: 9.2% vs. 1.9%, padj = 0.024) and thyroperoxidase antibodies (rs2285452A: 48.4% vs. 27.2%; padj = 0.028) in T1D patients. The rs2285452A variant has been previously associated with Hashimoto's thyroiditis in individuals without diabetes (7). However, it seems not to alter binding sites for transcription factors and the mechanisms causing predisposition to autoimmunity are still unclear. In addition, an association between polymorphisms of the IL-21R with diabetes in Japanese patients (45), and with SLE in a European-derived cohort were documented (9). *IL-21* is a cytokine with diverse and sometimes opposing effects (46-47). It can promote IFN-γ and T-bet expression via STAT1 activation, enhancing antibody production,
while also stimulating T and B cell proliferation and IL-10 production (a cytokine with immunosuppressive activity) through STAT3 activation. IL-21 can expand regulatory B cells (B10 cells), which suppress T cell responses, and induce apoptosis in B cells. Its effects on dendritic cells include both inhibition of maturation and promotion of IL-1β production. Other suppressive effects include the expansion of suppressor CD8 + T cells and the induction of IL-22 expression in CD4+ T cells. These varied actions may suggest that IL-21's role in autoimmunity may depend on the cytokine milieu and IL21R variants.

Although our analyses of extra-pancreatic autoantibodies were performed only in patients with T1D, the associations of the IL-21R and IL-17RA variants with T1D and autoantibodies targeting other nonpancreatic organs are probably due to extensive overlap in pathogenic mechanisms shared by different autoimmune disorders. A shared genetic background seems to confer predisposition across several autoimmune diseases. The reduced expression of IL17RA (14) and of IL21R on peripheral T cells in recent-onset T1D patients observed by our group may result from negative transcriptional regulation associated with the IL17RA and IL21R polymorphisms described here. Decreased expression of IL-21RA on peripheral B lymphocytes (46) was also observed in another autoimmune disease - SLE, associated with nephritis and high-titer anti-double-stranded DNA antibodies (48). However, we cannot exclude that the observed reduced surface expression may be due to receptor internalization following cytokine engagement, a process observed with other receptors like IL-7R (49). Factors such as receptor trafficking, glycosylation changes due to hyperglycemia (50), or differences between peripheral and tissue-specific immune environments may also contribute.

Limitations of the study include the heterogeneity and genetic admixture that is characteristic of the Brazilian population. Analyses were adjusted for covariates including sex, age (or duration of diabetes) and self-reported skin color when assessing T1D risk or frequency of autoantibodies in order to minimize the influence of variables. A second limitation is the lack of replication in an independent population.

Our study demonstrated that genetic variants in IL17RA and IL21R were associated with T1D susceptibility, and that variants of IL-21R also predispose to the development of nonpancreatic thyroid- and gastrointestinal-specific autoantibodies. Specifically, IL-17RA variant rs879577, related to T1D protection and lower frequency of anti-IA2, may aid in the prevention of T1D and deserves more studies. These findings highlight the complex interplay between cytokine receptor polymorphisms and autoantibody/autoimmune disease phenotypes, emphasizing the multifactorial nature of T1D pathogenesis involving multiple genetic and immunological networks. Future directions include functional analysis of the variants in large populations to elucidate the precise mechanism by which they confer autoimmune risk or protection and longitudinal follow-up of patients carrying the associated variants as biomarkers both of T1D progression and severity and for the development of other autoimmune diseases.
292

293 **CONCLUSION**

294 **Our study demonstrated that genetic variants in IL17RA and IL21R were associated with T1D**
295 **susceptibility and that variants of IL-21R also predispose to other autoimmune diseases affecting thyroid**
296 **and gastrointestinal tract tissues. In special the missense mutation rs879577, related to T1D protection**
297 **and lower frequency of anti-IA2 may provide more information about the pathogenesis of T1D. These**
298 **findings highlight the complex interplay between cytokine receptor polymorphisms and autoimmune**
299 **disease phenotypes, emphasizing the multifactorial nature of T1D pathogenesis involving multiple genetic**
300 **and immunological networks.**

301 **Future directions include longitudinal follow-up of patients carrying the associated variants as**
302 **biomarkers both of T1D progression and severity, as well as biomarkers for the development of other**
303 **autoimmune diseases.**

304 **ABBREVIATIONS**

305 IL-17A - Interleukin 17A

306 IL-17RA - Interleukin 17A receptor

307 IL-21 - Interleukin 21

308 IL-21R- Interleukin 21 receptor

309 Anti-GAD - Glutamic Acid Decarboxilase autoantibody

310 Anti-iA2 - Tyrosine Phosphatase-2 autoantibody

311 Anti-ZnT8 - Anti-Zinc Transporte 8 autoantibody

312 Anti-TPO - Anti-peroxidase autoantibody

313 Anti-TG - Anti-Thyroglobulin autoantibody

314 TRAB - anti-TSH receptor autoantibody

315 CEU population- Northern and Western European ancestry

316 YRI population- population from Nigeria (Africa)

317 MCP-monocyte chemoattractant protein

318 Interferon γ-induced protein 10 kDa (IP-10)

319 NOD- Non-Obese Diabetic mouse

320 PBMC - Peripheral Blood Mononuclear Cell

321 FOXP3 -Forkhead box protein P3

322 C/EBPB - C /enhancer-binding protein beta

323 YY1 - Yin Yang 1
324 ETS1 - ETS Proto-Oncogene 1

325 STAT1 - Signal transducers and activators of transcription

326

327 **Data Availability Statement:** All data generated or analyzed during this study are included in this
328 published article and its Supplementary Tables 1 to 7. Can also be requested to the corresponding
329 author mbeth@usp.br

330 **Ethics statement:** The study was approved by the Ethics Committee of Hospital das Clinicas da
331 Faculdade de Medicina da Universidade de São Paulo. CAPPesq CAAE 02038312.1.0000.0068). Written
332 informed consent was not required from the participants or the participants' legal guardians

333 **Author contributions:** Semzezem C, Gomes KFB, Chevillard C, Cunha-Neto E, Passos-Bueno MR
334 contributed to conceptualization and writing-review; Sezezem C, Santos AS, Correia MRS, Crisostomo
335 LD and Brito LS for laboratory analysis; Pauline Brochet, Chevillard C, Silva MER for statistical analysis;
336 Silva MER for conceptualization, analysis, writing-review, Funding acquisition and final editing,

337 **Funding:** Supported by the São Paulo Research Foundation (FAPESP 2012/14212) a non-profit
338 foundation

339 **Conflict-of-interest statement:** all the authors declare no conflict-of-interest

340 **Acknowledgements:** The authors would like to thank to Adriana Aparecida Rosa, Grecy de Paula and
341 Rodolfo Batista for technical assistance.

342 **Generative AI statement:** The author(s) declared that no Generative AI was used in the creation of this
343 manuscript.

344 **Scope statement**

345 We are submitting our article as a Research Topic for the collection of *Inflammatory Biomarkers in Type 1 Diabetes*. We appreciate the invitation and believe that our study, which analyzes the Th17 pathway, provides new insights into autoimmunity. Although interleukins of the Th17 pathway have been implicated in various autoimmune diseases, their role in T1D remains *underexplored and occasionally inconsistent*. Notably, these cells exhibit great plasticity and can transition into Tregs and Th1 cells. Our previous findings in Brazilian patients with T1D suggested that genetic polymorphisms in cytokines of the Th17 inflammatory pathway (IL-17, IL-21, IL-27) may exert a neutral or protective effect—particularly IL-23—in T1D susceptibility. This study, involving 639 patients with T1D and 653 healthy controls, evidenced the association of variants in both *IL-21R* and *IL-17RA* with T1D risk, predisposition. Additionally, SNPs in IL-21R were associated with extra-pancreatic autoantibodies, mainly anti-endomysium, anti-parietal cell, and anti-thyroid antibodies. Our data suggests that polymorphisms in *IL17RA* and *IL21R* genes may contribute to the pathophysiology of T1D and influence the presence of both pancreatic and extra-pancreatic autoantibodies, highlighting their potential role as inflammatory biomarkers in T1D.

358

359 **REFERENCES**

360 1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. *Lancet*. 2014 Jan 4;383(9911):69-82. doi:
361 10.1016/S0140-6736(13)60591-7. Epub 2013 Jul 26. PMID: 23890997; PMCID: PMC4380133.
362 2. Silva ME, Mory D, Davini E. Marcadores genéticos e auto-imunes do diabetes melito tipo 1: da teoria para a prática [Genetic and humoral autoimmunity markers of type 1 diabetes: from theory to practice].
363 Arq Bras Endocrinol Metabol. 2008 Mar;52(2):166-80. Portuguese. doi: 10.1590/s0004-3646.27302008000200004. PMID: 18438527.

366 3. Alves LI, Davini E, Correia MR, Fukui RT, Santos RF, Cunha MR, et al. Autoantibodies and high-risk HLA susceptibility markers in first-degree relatives of Brazilian patients with type 1 diabetes mellitus: a progression to disease based study. *J Clin Immunol*. 2012 Aug;32(4):778-85. doi: 10.1007/s10875-3689-012-9673-4. Epub 2012 Mar 9. PMID: 22402866.

370 4. Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. *Biomed Pharmacother*. 2018 May;101:287-292. doi: 10.1016/j.biopha.2018.02.103. Epub 2018 Feb 27. PMID: 29499402.

373 5. Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol. 2019 May;41(3):283-297. doi: 10.1007/s00281-019-00733-8. Epub 2019 Mar 19. Erratum in: Semin Immunopathol. 2019 May;41(3):299. doi: 10.1007/s00281-019-00746-3. PMID: 30891627.

377 6. Koh CH, Kim BS, Kang CY, Chung Y, Seo H. IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials. *Immune Netw*. 2024 Jan 19;24(1):e2. doi: 10.4110/in.2024.24.e2.

379 7. Zhang J, Xiao WX, Zhu YF, Muhali FS, Xiao L, Jiang WJ, et al. Polymorphisms of interleukin-21 and interleukin-21-receptor genes confer risk for autoimmune thyroid diseases. *BMC Endocr Disord*. 2013 Jul 29;13:26. doi: 10.1186/1472-6823-13-26. PMID: 23889847; PMCID: PMC3766107.

382 8. Bisoendial R, Lubberts E. A Mechanistic Insight into the Pathogenic Role of Interleukin 17A in Systemic Autoimmune Diseases. *Mediators Inflamm*. 2022 May 17;2022:6600264. doi: 10.1155/2022/6600264. PMID: 35620115; PMCID: PMC9129985.

385 9. Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Langefeld CD, et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. *Arthritis Rheum*. 2009 Aug;60(8):2402-7. doi: 10.1002/art.24658. PMID: 19644854; PMCID: PMC2782592.

388 10. Gharibi T, Hosseini A, Marofi F, Oraei M, Jahandideh S, Abdollahpour-Alitappeh M, et al. IL-21 and IL-21-producing T cells are involved in multiple sclerosis severity and progression. *Immunol Lett*. 2019 Dec;216:12-20. doi: 10.1016/j.imlet.2019.09.003. Epub 2019 Sep 20. Erratum in: *Immunol Lett*. 2021 Apr;232:67. doi: 10.1016/j.imlet.2020.12.013. PMID: 31545959.

392 11. Li J, Xu L, Zhao W, Pan J, Lu J, Lu H, et al. Serum IL-17A concentration and a IL17RA single nucleotide polymorphism contribute to the risk of autoimmune type 1 diabetes. *Diabetes Metab Res Rev*. 2022 Sep;38(6):e3547. doi: 10.1002/dmrr.3547. Epub 2022 May 25. PMID: 35583128

395 12. Honkanen J, Nieminen JK, Gao R, Luopajarvi K, Salo HM, Ilonen J, et al. IL-17 immunity in human type 1 diabetes. *J Immunol*. 2010 Aug 1;185(3):1959-67. doi: 10.4049/jimmunol.1000788. Epub 2010 Jun 30. PMID: 20592279.

398 13. Arif S, Moore F, Marks K, Bouckenooghe T, Dayan CM, Planas R, et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. *Diabetes*. 2011 Aug;60(8):2112-9. doi: 10.2337/db10-1643. Epub 2011 Jun 9. PMID: 21659501; PMCID: PMC3142078.

402 14. Fores JP, Crisostomo LG, Orii NM, Santos AS, Fukui RT, Matioli SR, et al. Th17 pathway in recent-onset autoimmune diabetes. *Cell Immunol*. 2018 Feb;324:8-13. doi: 10.1016/j.cellimm.2017.11.005. Epub 2017 Nov 15. PMID: 29183760.

405 15. Costa VS, Santos AS, Fukui RT, Mattana TC, Matioli SR, Silva ME. Protective effect of interleukin-23A (IL23A) haplotype variants on type 1A diabetes mellitus in a Brazilian population. *Cytokine*. 2013 May;62(2):327-33. doi: 10.1016/j.cyto.2013.03.015. Epub 2013 Apr 9. PMID: 23579029

408 16. Mainardi-Novo DT, Santos AS, Fukui RT, Gamberini M, Correia MR, Ruiz MO, et al. The PTPN22 1858T allele but not variants in the proximal promoter region of IL-21 gene is associated with the
410 susceptibility to type 1 diabetes and the presence of autoantibodies in a Brazilian cohort. *Clin Exp Immunol*. 2013 Apr;172(1):16-22. doi: 10.1111/cei.12030. PMID: 23480181; PMCID: PMC3719927.

412 17. Santos AS, Melo ME, Crisóstomo LG, Fukui RT, Matioli SR, Silva ME. Lack of association between IL27 gene variants and type 1 diabetes susceptibility. *Cytokine*. 2013 Feb;61(2):349-52. doi: 10.1016/j.cyto.2012.12.003. Epub 2013 Jan 5. PMID: 23294976.

415 18. Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. *Diabetes*. 2009 Jun;58(6):1302-11. doi: 10.2337/db08-1113. Epub 2009 Mar 16. PMID: 19289457; PMCID: PMC2682686.

418 19. Jörns A, Ishikawa D, Teraoku H, Yoshimoto T, Wedekind D, Lenzen S. Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or/and anti-IL-6 in the IDDM rat model of type 1 diabetes. *BMC Med*. 2020 Feb 28;18(1):33. doi: 10.1186/s12916-020-1503-6. PMID: 32106855; PMCID: PMC7047363.

422 20. Mensah-Brown EP, Shahin A, Al-Shamisi M, Wei X, Lukic ML. IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin. *Eur J Immunol*. 2006 Jan;36(1):216-23. doi: 10.1002/eji.200535325. PMID: 16358360.

425 21. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. *Proc Natl Acad Sci U S A*. 2008 Sep 16;105(37):14028-33. doi: 10.1073/pnas.0804358105. Epub 2008 Sep 8. PMID: 18779574; PMCID: PMC2544573.

428 22. Sutherland AP, Van Belle T, Wurster AL, Suto A, Michaud M, Zhang D, et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. *Diabetes*. 2009 May;58(5):1144-55. doi: 10.2337/db08-0882. Epub 2009 Feb 10. PMID: 19208913; PMCID: PMC2671036.

431 23. Bending D, De la Peña H, Veldhoen M, Phillips JM, Uyttenhove C, Stockinger B, et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. *J Clin Invest*. 2009 Mar;119(3):565-72. doi: 10.1172/JCI37865. Epub 2009 Feb 2. PMID: 19188681; PMCID: PMC2648686

435 24. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. *Eur J Immunol*. 2009 Jan;39(1):216-24. doi: 10.1002/eji.200838475. PMID: 19130584; PMCID: PMC2755057.

439 25. Nikoopour E, Schwartz JA, Huszarik K, Sandrock C, Krougly O, Lee-Chan E, et al. Th17 polarized cells from nonobese diabetic mice following mycobacterial adjuvant immunotherapy delay type 1 diabetes. *J Immunol*. 2010 May 1;184(9):4779-88. doi: 10.4049/jimmunol.0902822. Epub 2010 Apr 2. PMID: 20363968.

443 26. Lau K, Benitez P, Ardisson A, Wilson TD, Collins EL, Lorca G, et al 3rd. Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias. *J Immunol*. 2011 Mar 15;186(6):3538-46. doi: 10.4049/jimmunol.1001864. Epub 2011 Feb 11. PMID: 21317395.

446 27. American Diabetes Association. (2) Classification and diagnosis of diabetes. *Diabetes Care*. 2015 Jan;38 Suppl:S8-S16. doi: 10.2337/dc15-S005. PMID: 25537714.

448 28. Gomes KF, Santos AS, Semzezem C, Correia MR, Brito LA, Ruiz MO, et al. The influence of population stratification on genetic markers associated with type 1 diabetes. *Sci Rep*. 2017 Mar 6;7:43513. doi: 10.1038/srep43513. PMID: 28262800; PMCID: PMC5338024.

451 29. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. *Genome Res*. 2005 Nov;15(11):1592-3. doi: 10.1101/gr.4413105. PMID: 16251469; PMCID: PMC1310647.

453 30. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*. 2005 Jan 15;21(2):263-5. doi: 10.1093/bioinformatics/bth457. Epub 2004 Aug 5. PMID: 15297300.

456 31. *Genomic DNA extraction was performed by salting-out in blood leukocytes* - Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*. 1988;16(3):1215. doi: 10.1093/nar/16.3.1215.
459 32. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. *Proc Natl Acad Sci U S A.* 2005 Apr 5;102(14):5126-31. doi: 10.1073/pnas.0501701102. Epub 2005 Mar 28. PMID: 15795373; PMCID: PMC556008.

462 33. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. *J Biol Chem.* 2003 Jan 17;278(3):1910-4. doi: 10.1074/jbc.M207577200. Epub 2002 Nov 3. PMID: 12417590.

465 34. Amatya N, Garg AV, Gaffen SL. IL-17 Signaling: The Yin and the Yang. *Trends Immunol.* 2017 May;38(5):310-322. doi: 10.1016/j.it.2017.01.006. Epub 2017 Feb 20. PMID: 28254169; PMCID: PMC5411326.

468 35. Oldfield AJ, Yang P, Conway AE, Cinghu S, Freudenberg JM, Yellaboina S, et al. Histone-fold domain protein NF-Y promotes chromatin accessibility for cell type-specific master transcription factors. *Mol Cell.* 2014 Sep 4;55(5):708-22. doi: 10.1016/j.molcel.2014.07.005. Epub 2014 Aug 14. PMID: 25132174; PMCID: PMC4157648.

472 36. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. *Gut.* 2003 Jan;52(1):65-70. doi: 10.1136/gut.52.1.65. PMID: 12477762; PMCID: PMC1773503.

475 37. Paula Sanchez Zanotti M, Cataldi de Alcântara C, Junko Inoue C, Piantoni Gonçalves B, Rabello Espinosa B, Luiz Cândido de Souza Cassela P, et al. Involvement of IL17A and IL17RA variants in interleukin-17A levels and disease activity in ulcerative colitis. *Cytokine.* 2024 Oct;182:156716. doi: 10.1016/j.cyto.2024.156716. Epub 2024 Aug 6. PMID: 39111114.

479 38. Somers J, Ruttens D, Verleden SE, Vandermeulen E, Piloni D, Wauters E, et al. Interleukin-17 receptor polymorphism predisposes to primary graft dysfunction after lung transplantation. *J Heart Lung Transplant.* 2015 Jul;34(7):941-9. doi: 10.1016/j.healun.2015.03.009. Epub 2015 Mar 26. PMID: 25935436

483 39. Wu X, Cheng Y, Li T, Wang Z, Liu JY. In vitro identification of DNA-binding motif for the new zinc finger protein AtYY1. *Acta Biochim Biophys Sin* (Shanghai). 2012 Jun;44(6):483-9. doi: 10.1093/abbs/gms020. Epub 2012 Apr 16. PMID: 22508367

486 40. Lew BL, Cho HR, Haw S, Kim HJ, Chung JH, Sim WY. Association between IL17A/IL17RA Gene Polymorphisms and Susceptibility to Alopecia Areata in the Korean Population. *Ann Dermatol.* 2012 Feb;24(1):61-5. doi: 10.5021/ad.2012.24.1.61

489 41. Maher SA, AbdAllah NB, Ageeli EA, Riad E, Kattan SW, Abdelaal S, Abdelfatah W, Ibrahim GA, Toraih EA, Awadalla GA, Fawzy MS, Ibrahim A. Impact of Interleukin-17 Receptor A Gene Variants on Asthma Susceptibility and Clinical Manifestations in Children and Adolescents. *Children* (Basel). 2024 May 28;11(6):657. doi: 10.3390/children11060657

493 42. Labikova J, Vcelakova J, Ulmannova T, Petruzelkova L, Kolouskova S, Stechova K. The cytokine production of peripheral blood mononuclear cells reflects the autoantibody profile of patients suffering from type 1 diabetes. *Cytokine.* 2014 Oct;69(2):189-95. doi: 10.1016/j.cyto.2014.06.013. Epub 2014 Jul 1. PMID: 24993165.

497 43. Zheng Z, Zheng F. A complex auxiliary: IL-17/Th17 signaling during type 1 diabetes progression. *Mol Immunol.* 2019 Jan;105:16-31. doi: 10.1016/j.molimm.2018.11.007.

499 44. Kim CJ, Lee CG, Jung JY, Ghosh A, Hasan SN, Hwang SM, et al. The Transcription Factor Ets1 Suppresses T Follicular Helper Type 2 Cell Differentiation to Halt the Onset of Systemic Lupus Erythematosus. *Immunity.* 2018 Dec 18;49(6):1034-1048.e8. doi: 10.1016/j.immuni.2018.10.012. Erratum in: *Immunity*. 2019 Jan 15;50(1):272. doi: 10.1016/j.immuni.2018.12.023. PMID: 30566881.

503 45. Asano K, Ikegami H, Fujisawa T, Nishino M, Nojima K, Kawabata Y, et al. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. *Hum Immunol.* 2007 May;68(5):384-91. doi: 10.1016/j.humimm.2007.01.009
506 46.Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. *Nat Rev Drug*

507 *Discov.* 2014 May;13(5):379-95. doi: 10.1038/nrd4296. Epub 2014 Apr 22. PMID: 24751819.

508 47.Lin JX, Leonard WJ. The Common Cytokine Receptor γ Chain Family of Cytokines. *Cold Spring Harb*

509 *Perspect Biol.* 2018 Sep 4;10(9):a028449. doi: 10.1101/cshperspect.a028449. PMID: 29038115;

510 PMCID: PMC6120701.

511 48.Mitoma H, Horiuchi T, Kimoto Y, Tsukamoto H, Uchino A, Tamimoto Y, et al. Decreased expression of
512 interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus. *Int J Mol Med.*

513 2005 Oct;16(4):609-15. PMID: 16142394.

514 49. Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, Giardina S, et al. IL-7 therapy

515 dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates.

516 *Blood.* 2003 Mar 15;101(6):2294-9. doi: 10.1182/blood-2002-07-2297. Epub 2002 Oct 31. PMID:

517 12411295.

518 50. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications.

519 Korean J Physiol Pharmacol. 2014 Feb;18(1):1-14. doi: 10.4196/kjpp.2014.18.1

520

521

522

523

524

525 Figure 1 Legend:

526 Demographic characteristics of patents with Type 1 diabetes (T1D) and Health Controls
<table><caption>Table 1- Genotypic frequencies of the variants in *IL-17RA* and *IL-21R* in patients with T1D and Control subjects and their association with T1D susceptibility</caption><thead><tr><th>Genes</th><th>Variants</th><th>Genotypes</th><th>Controls (N%)</th><th>T1D (N%)</th><th>OR</th><th>CI 95%</th><th>p</th><th>OR adj</th><th>CI 95% adj</th><th>p adj</th></tr></thead><tbody><tr><td rowspan="6">IL17RA</td><td rowspan="2">rs5748863</td><td>AG+GG</td><td>465 (72.7)</td><td>431 (69.2)</td><td>0.845</td><td>(0.662 - 1.077)</td><td>0.174</td><td>0.93</td><td>(0.72 - 1.2)</td><td>0.59</td></tr><tr><td>GG</td><td>127 (19.8)</td><td>125 (20.1)</td><td>1.014</td><td>(0.769 - 1.336)</td><td>0.922</td><td>1.12</td><td>(0.84 - 1.51)</td><td>0.433</td></tr><tr><td rowspan="2">rs2241049</td><td>AG+GG</td><td>357 (56.2)</td><td>379 (63.3)</td><td>1.342</td><td>(1.068 - 1.686)</td><td>0.012*</td><td>1.42</td><td>(1.11 - 1.81)</td><td><strong>0.005*</strong></td></tr><tr><td>GG</td><td>85 (13.4)</td><td>94 (15.7)</td><td>1.204</td><td>(0.877 - 1.654)</td><td>0.25</td><td>1.22</td><td>(0.87 - 1.7)</td><td>0.259</td></tr><tr><td rowspan="2">rs879577</td><td>AG+AA</td><td>322 (52.2)</td><td>302 (49.3)</td><td>0.89</td><td>(0.711 - 1.113)</td><td>0.305</td><td>0.96</td><td>(0.76 - 1.21)</td><td>0.703</td></tr><tr><td>AA</td><td>72 (11.7)</td><td>42 (6.9)</td><td>0.557</td><td>(0.374 - 0.829)</td><td>0.004</td><td>0.61</td><td>(0.4 - 0.93)</td><td><strong>0.021*</strong></td></tr><tr><td rowspan="2">rs5992628</td><td>TG+TT</td><td>439 (69.8)</td><td>420 (68.6)</td><td>0.947</td><td>(0.744 - 1.205)</td><td>0.656</td><td>0.9</td><td>(0.7 - 1.16)</td><td>0.426</td></tr><tr><td>TT</td><td>110 (17.5)</td><td>134 (21.9)</td><td>1.323</td><td>(0.999 - 1.752)</td><td>0.051</td><td>1.26</td><td>(0.94 - 1.7)</td><td>0.12</td></tr><tr><td rowspan="6">IL-21R</td><td rowspan="2">rs2214537</td><td>CG+GG</td><td>403 (64.9)</td><td>370 (62.7)</td><td>0.91</td><td>(0.72 - 1.15)</td><td>0.429</td><td>0.95</td><td>(0.74 - 1.21)</td><td>0.665</td></tr><tr><td>GG</td><td>99 (15.9)</td><td>90 (15.3)</td><td>0.949</td><td>(0.696 - 1.295)</td><td>0.742</td><td>1.02</td><td>(0.73 - 1.41)</td><td>0.928</td></tr><tr><td rowspan="2">rs7199138</td><td>GC+CC</td><td>325 (51.3)</td><td>345 (56.5)</td><td>1.229</td><td>(0.983 - 1.537)</td><td>0.07</td><td>1.33</td><td>(1.05 - 1.68)</td><td><strong>0.018*</strong></td></tr><tr><td>CC</td><td>63 (10)</td><td>64 (10.CV5)</td><td>1.059</td><td>(0.733 - 1.528)</td><td>0.761</td><td>1.08</td><td>(0.73 - 1.59)</td><td>0.693</td></tr><tr><td rowspan="2">rs3093315</td><td>TG+TT</td><td>389 (60.4)</td><td>357 (57.3)</td><td>0.88</td><td>(0.703 - 1.101)</td><td>0.262</td><td>0.84</td><td>(0.67 - 1.07)</td><td>0.158</td></tr><tr><td>TT</td><td>77 (12)</td><td>81 (13)</td><td>1.1</td><td>(0.788 - 1.536)</td><td>0.574</td><td>1.08</td><td>(0.76 - 1.54)</td><td>0.662</td></tr><tr><td rowspan="2">rs2285452</td><td>AG+AA</td><td>308 (48.7)</td><td>300 (48.9)</td><td>1.008</td><td>(0.807 - 1.259)</td><td>0.942</td><td>1.02</td><td>(0.81 - 1.29)</td><td>0.851</td></tr><tr><td>AA</td><td>52 (8.2)</td><td>49 (8)</td><td>0.969</td><td>(0.645 - 1.456)</td><td>0.88</td><td>1.01</td><td>(0.66 - 1.56)</td><td>0.958</td></tr></tbody></table>

T1D: type 1 diabetes patients. OR= odds ratio. CI= confidence interval. adj= adjusted for age gender and ancestry.

527

528

529

530

531

532

533

534
<table><caption>Table 2- Associations of *IL-17RA* variants with pancreatic autoantibodies in patients with type 1 diabetes</caption><thead><tr><th>IL-17RA<br>Variants</th><th>Genotypes</th><th>Anti-GAD65<br>N (%)</th><th>p</th><th>Anti-Znt8<br>N (%)</th><th>p</th><th>Anti-IA2<br>N(%)</th><th>p</th><th>OR adj</th><th>IC (95%)</th><th>p adj</th></tr></thead><tbody><tr><td rowspan="4">rs5748863</td><td>AA</td><td>79 (53.0)</td><td rowspan="4">0.168</td><td>41 (42.2)</td><td rowspan="4">0.165</td><td>62 (44.3)</td><td rowspan="2"><strong>0.013*</strong></td><td rowspan="4">0.56</td><td rowspan="4">(0.32 - 0.99)</td><td rowspan="2"><strong>0.047*</strong></td></tr><tr><td>AG</td><td>123 (46.8)</td><td>86 (53.4)</td><td>116 (47.0)</td></tr><tr><td>GG</td><td>45 (41.3)</td><td>35 (44.3)</td><td>32 (30.2)</td><td>178(46%)</td></tr><tr><td>AA/AG<br>GG</td><td></td><td></td><td></td><td>32 (30.2)</td><td><strong>0.004*</strong></td></tr><tr><td rowspan="3">rs2241049</td><td>AA</td><td>97 (52.4)</td><td rowspan="3">0.212</td><td>56 (47.0)</td><td rowspan="3">0.978</td><td>77 (43.0)</td><td rowspan="3">0.919</td><td rowspan="3"></td><td rowspan="3"></td><td rowspan="3"><strong>0.010*</strong></td></tr><tr><td>AG</td><td>109 (46.3)</td><td>72 (48.3)</td><td>93 (42.0)</td></tr><tr><td>GG</td><td>34 (41.4)</td><td>26 (48.1)</td><td>31 (40.2)</td></tr><tr><td rowspan="4">rs879577</td><td>GG</td><td>122 (47.8)</td><td rowspan="4">0.976</td><td>80 (49.3)</td><td rowspan="4">0.934</td><td>113 (47.1)</td><td rowspan="4">0.053</td><td rowspan="4"></td><td rowspan="4"></td><td rowspan="4"></td></tr><tr><td>AG</td><td>107 (47.8)</td><td>70 (47.2)</td><td>80 (37.2)</td></tr><tr><td>AA</td><td>17 (45.9)</td><td>11 (47.8)</td><td>11 (32.2)</td></tr><tr><td>GG<br>AG/AA</td><td></td><td></td><td>113 (47.0)<br>91 (36.6)</td><td>0.018*</td></tr><tr><td rowspan="3">rs5992628</td><td>GG</td><td>73 (47.0)</td><td rowspan="3">0.581</td><td>49 (45.3)</td><td rowspan="3">0.619</td><td>60 (40.2)</td><td rowspan="3">0.2</td><td rowspan="3"></td><td rowspan="3"></td><td rowspan="3"><strong>0.043*</strong></td></tr><tr><td>TG</td><td>113 (47.0)</td><td>69 (47.5)</td><td>91 (40.4)</td></tr><tr><td>TT</td><td>61 (52.5)</td><td>41 (52.5)</td><td>55 (50.0)</td></tr></tbody></table>

Islet Autoantibodies: anti-glutamic acid decarboxylase (anti-GAD65), anti-tyrosine phosphatase (anti-IA2), anti-zinc transporter 8 (Anti-ZnT8)
<table><caption>Table 3- Genotypic frequencies of the variants in *IL-21R* in patients with T1D and control subjects and their association with T1D susceptibility.</caption><thead><tr><th>Variant</th><th>Genotypes</th><th>Controls<br>N (%)</th><th>T1D<br>N (%)</th><th>OR</th><th>CI 95%</th><th>p</th><th>OR adj</th><th>CI 95% adj</th><th>p adj</th></tr></thead><tbody><tr><td rowspan="2">rs2214537</td><td>CG+GG</td><td>403 (64.9)</td><td>370 (62.7)</td><td>0.91</td><td>(0.72 - 1.15)</td><td>0.429</td><td>0.95</td><td>(0.74 - 1.21)</td><td>0.665</td></tr><tr><td>GG</td><td>99 (15.9)</td><td>90 (15.3)</td><td>0.949</td><td>(0.696 - 1.295)</td><td>0.742</td><td>1.02</td><td>(0.73 - 1.41)</td><td>0.928</td></tr><tr><td rowspan="2">rs7199138</td><td>GC+CC</td><td>325 (51.3)</td><td>345 (56.5)</td><td>1.229</td><td>(0.983 - 1.537)</td><td>0.07</td><td>1.33</td><td>(1.05 - 1.68)</td><td><strong>0.018*</strong></td></tr><tr><td>CC</td><td>63 (10)</td><td>64 (10.5)</td><td>1.059</td><td>(0.733 - 1.528)</td><td>0.761</td><td>1.08</td><td>(0.73 - 1.59)</td><td>0.693</td></tr><tr><td rowspan="2">rs3093315</td><td>TG+TT</td><td>389 (60.4)</td><td>357 (57.3)</td><td>0.88</td><td>(0.703 - 1.101)</td><td>0.262</td><td>0.84</td><td>(0.67 - 1.07)</td><td>0.158</td></tr><tr><td>TT</td><td>77 (12)</td><td>81 (13)</td><td>1.1</td><td>(0.788 - 1.536)</td><td>0.574</td><td>1.08</td><td>(0.76 - 1.54)</td><td>0.662</td></tr><tr><td rowspan="2">rs2285452</td><td>AG+AA</td><td>308 (48.7)</td><td>300 (48.9)</td><td>1.008</td><td>(0.807 - 1.259)</td><td>0.942</td><td>1.02</td><td>(0.81 - 1.29)</td><td>0.851</td></tr><tr><td>AA</td><td>52 (8.2)</td><td>49 (8)</td><td>0.969</td><td>(0.645 - 1.456)</td><td>0.88</td><td>1.01</td><td>(0.66 - 1.56)</td><td>0.958</td></tr></tbody></table>

T1D: type 1 diabetes patients. OR= odds ratio. CI= confidence interval. adj= adjusted for age gender and ancestry.

537

538

539

540

541

542

543

544

545

546
<table><caption>Table 4: Associations of IL-21R variants with extra-pancreatic autoantibodies in patients with type 1 diabetes</caption><thead><tr><th>IL-21R Variants</th><th>Genotypes</th><th>Autoantibodies</th><th>Positive N(%)</th><th>Negative N(%)</th><th>p</th><th>OR adj</th><th>CI (95%) adj</th><th>p adj</th></tr></thead><tbody><tr><td>rs2214537</td><td>CC</td><td rowspan="2">Anti- parietal cell</td><td>15 (16.9)</td><td>74 (83.1)</td><td rowspan="2">0.002*</td><td rowspan="2">0.24</td><td rowspan="2">(0.09 - 059)</td><td rowspan="2"><strong>&lt;0.001*</strong></td></tr><tr><td></td><td>CG/GG</td><td>8 (4.9)</td><td>156 (95.1)</td></tr><tr><td>rs3093315</td><td>GG</td><td rowspan="2">TRAb</td><td>2 (1.9)</td><td>105 (98.1)</td><td rowspan="2">0.016*</td><td rowspan="2">5.89</td><td rowspan="2">(1.26 - 27.61)</td><td rowspan="2"><strong>0.024*</strong></td></tr><tr><td></td><td>TG/TT</td><td>13 (9.2)</td><td>128 (90.8)</td></tr><tr><td>rs2285452</td><td>GG</td><td rowspan="2">Ant-endomysium</td><td>11 (7.3)</td><td>139 (92.7)</td><td rowspan="2">0.02*</td><td rowspan="2">0.17</td><td rowspan="2">(0.04 - 0.8)</td><td rowspan="2"><strong>0.025*</strong></td></tr><tr><td></td><td>AG/AA</td><td>2 (1.3)</td><td>147 (98.7)</td></tr><tr><td>rs2285452</td><td>GG/AG</td><td rowspan="2">Anti-TPO</td><td>97 (27.2)</td><td>260 (78.8)</td><td rowspan="2">0.012*</td><td rowspan="2">2.38</td><td rowspan="2">(1.1 - 5.13)</td><td rowspan="2"><strong>0.028*</strong></td></tr><tr><td></td><td>AA</td><td>15 (48.4)</td><td>16 (51.6)</td></tr></tbody></table>

OR= odds ratio, CI= confidence interval, adj= adjusted for gender, self-reported color and duration of diabetes

TRAb- Thyroid Stimulating Hormone autoantibody

547

548

549

550

551

552